Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

TCT: Late catch-up with DES does existmore common in Cypher than Taxus

SAN FRANCISCOThere is added accumulation of neointima, or so-called late catch-up, after six to nine months in patients who received drug-eluting stents (DES), according to an analysis presented this week at the 2009 Transcatheter Cardiovascular Therapeutics scientific meeting.

TCT: Radial PCI approach should be adopted for clinical, financial reasons

SAN FRANCISCOJeffrey J. Popma, MD, stated that it is clinically and fiscally beneficial for U.S. interventionalists to use the radial approach for PCI procedures at the 2009 meeting of the Transcatheter Cardiovascular Therapeutics this week.

TCT: Xience performs much better than Taxus, except in diabetics

SAN FRANCISCOAbbotts Xience V stent demonstrates enhanced safety and efficacy compared with Boston Scientifics Taxus Express without routine angiographic follow-up, according to the one-year clinical data of SPIRIT IV presented at the late-breaking clinical trials session on Wednesday at the Transcatheter Cardiovascular Therapeutics conference. However, both stents produced positive clinical outcomes.

TCT: Procedure time is best gauge of angio competence

SAN FRANCISCOProcedure time is the most useful indicator of experience in angiography from the femoral route, although radial procedure times do not improve significantly with training, according to a U.K. study presented this week at the 2009 Transcatheter Cardiovascular Therapeutics scientific symposium.

TCT: Being black is independent predictor of post-PCI adverse events

SAN FRANCISCOBlacks were found to have worse long-term cardiovascular outcomes and mortality, following PCI, irrespective of differences in baseline cardiovascular risk factors, socioeconomic status and healthcare access, based on a study presentation Tuesday at the annual Transcatheter Cardiovascular Therapeutics meeting.

TCT: Dual-antiplatelet therapyis two years superior to one for late thrombosis?

SAN FRANCISCOA two-year dual-antiplatelet regimen with aspirin and clopidogrel can prevent the occurrence of very late stent thrombosis after PCI with drug-eluting stents (DES), according to the TYCOON (Two-Year ClOpidOgrel Need) registry presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting this week.

TCT: Stent reps in cath lab influence stent selectionshould they be kicked out?

SAN FRANCISCOWhen stent manufacturers send their representatives to the cath lab, their presence can influence the interventionalists choice of stent, according to a study presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

ESC: Sanofi's otamixaban performs well for ACS patientsis it necessary?

The SEPIA-ACS1 TIMI 42 study presented Sunday at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, shows that otamixaban is a promising new anti-clotting drug for patients with acute coronary syndromes (ACS). But, some experts are questioning the need for another anticoagulant on the market.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.